MetLife vs AbbVie

Side-by-side comparison of AI visibility scores, market position, and capabilities

AbbVie leads in AI visibility (90 vs 56)

MetLife

ChallengerInsurance Tech

Life Insurance

New York global insurance (NYSE: MET) at $70.986B 2024 revenue; PineBridge $1.2B acquisition ($100B AUM, Dec 2024) and Mesirow ($6B) expanding MetLife Investment Management under "New Frontier" strategy competing with Prudential.

AI VisibilityBeta
Overall Score
C56
Category Rank
#1 of 1
AI Consensus
55%
Trend
down
Per Platform
ChatGPT
59
Perplexity
48
Gemini
52

About

MetLife, Inc. is a New York City, New York-based global insurance and financial services company — publicly traded on the New York Stock Exchange (NYSE: MET) as an S&P 500 component — providing life insurance, dental and vision insurance, retirement solutions, group benefits, and asset management through approximately 45,000 employees serving approximately 90 million customers in over 60 countries. In fiscal year 2024, MetLife reported $70.986 billion in total revenue. Founded in 1868 as the Metropolitan Life Insurance Company to serve Civil War-era disabled sailors and soldiers, MetLife converted from a mutual company to a publicly traded corporation in 2000 (ending 85 years as a mutual). CEO Michel A. Khalaf (since 2019) launched the "New Frontier" strategy in 2024, focused on accelerating growth through digital transformation, enhanced customer experiences, and strategic acquisitions in asset management. MetLife's asset management arm, MetLife Investment Management (MIM), announced the $1.2 billion acquisition of PineBridge Investments from Pacific Century Group in December 2024 — adding approximately $100 billion in AUM to MIM's platform ($800M at close, $200M tied to 2025 financial metrics, $200M multi-year earnout). In January 2025, MetLife acquired investment teams from Mesirow managing $6 billion in assets. MetLife operates through six segments: Group Benefits (employer-sponsored life, dental, vision, disability), Retirement and Income Solutions (RIS, pension risk transfer, structured settlements), Asia, Latin America, EMEA, and MetLife Holdings (run-off blocks).

Full profile

AbbVie

LeaderHealthcare

General

Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.

AI VisibilityBeta
Overall Score
A90
Category Rank
#9 of 1167
AI Consensus
60%
Trend
stable
Per Platform
ChatGPT
99
Perplexity
99
Gemini
83

About

AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.

Full profile

AI Visibility Head-to-Head

56
Overall Score
90
#1
Category Rank
#9
55
AI Consensus
60
down
Trend
stable
59
ChatGPT
99
48
Perplexity
99
52
Gemini
83
52
Claude
96
67
Grok
95

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.